Best Insurance Stocks To Invest In Right Now

tags:REIS,ATRS,SWZ,

When the masses descend upon snow-covered Davos for the World Economic Forum’s annual gathering, Esther Heldstab is determined to swim against the tide.

The purveyor of tourist mementos on the town’s main street is one of the few shopkeepers who won’t hand over their keys to multinational conglomerates who transform shoe stores and bakeries into lounges and cocktail party space for the week.

While the likes of Zurich Insurance, Credit Suisse and Deutsche Bank take over prime space on Promenade, Heldstab and her sister who run Swissalp Fantasy at no. 79 -- where the window display features a stuffed Bernese mountain dog -- simply stay put.

#lazy-img-322660176:before{padding-top:60.83333333333334%;}

“On this mile, you can pretty much ask what you want,” said Heldstab. No one interviewed for this story would speak on the record about rental costs, though Heldstab said should could double her money if she rented out her shop in a half-timber house festooned with Swiss crosses. Still, “it’s so nice when the people from all over the world come -- it’s like Hollywood.”

Best Insurance Stocks To Invest In Right Now: Reis, Inc(REIS)

Advisors' Opinion:

• [By Logan Wallace]

  Reis (NASDAQ:REIS) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

• [By Rich Smith]

  Shares of commercial real estate data provider Reis, Inc. (NASDAQ:REIS) soared 32.2% to close at $23 on the nose today, after Moody's Corporation (NYSE:MCO) announced it would acquire the company for (drumroll, please)...$23 a share!

• [By Shane Hupp]

  Emerald Expositions Events (NYSE: EEX) and Reis (NASDAQ:REIS) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

• [By Stephan Byrd]

  ValuEngine upgraded shares of Reis (NASDAQ:REIS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

  Several other research analysts also recently commented on the company. Zacks Investment Research downgraded Reis from a hold rating to a strong sell rating in a research note on Friday, May 11th. BidaskClub raised Reis from a buy rating to a strong-buy rating in a research note on Friday, July 6th. Finally, B. Riley lowered their target price on Reis to $26.00 and set a buy rating for the company in a research note on Tuesday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $22.00.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Reis (REIS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Insurance Stocks To Invest In Right Now: Antares Pharma, Inc.(ATRS)

Advisors' Opinion:

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Antares Pharma (ATRS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  Antares Pharma (NASDAQ:ATRS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

• [By Shane Hupp]

  HC Wainwright set a $5.00 price objective on Antares Pharma (NASDAQ:ATRS) in a research report released on Friday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

• [By Logan Wallace]

  BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

• [By Stephan Byrd]

  Antares Pharma, Inc. (NASDAQ:ATRS) Director Jacques Gonella sold 300,000 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The stock was sold at an average price of $2.47, for a total value of $741,000.00. Following the completion of the sale, the director now directly owns 11,936,413 shares of the company’s stock, valued at approximately $29,482,940.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

• [By Max Byerly]

  Antares Pharma (NASDAQ:ATRS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.

Best Insurance Stocks To Invest In Right Now: Swiss Helvetia Fund, Inc. (SWZ)

Advisors' Opinion:

• [By Logan Wallace]

  Swiss Helvetia Fund, Inc. Common Stock (NYSE:SWZ) declared a Semi-Annual dividend on Tuesday, June 12th, Zacks reports. Investors of record on Friday, June 22nd will be paid a dividend of 0.203 per share by the closed-end fund on Friday, June 29th. The ex-dividend date of this dividend is Thursday, June 21st.